BACKGROUND Despite the well-known fact that antibiotics (AB) are not effective against viruses, many patients ask for - and all too often doctors provide - AB for treating URTIs. Over-prescribing of AB is one of the key causes for the development of bacterial resistance, which the U.S. Centers for Disease Control and Prevention (CDC) calls "one of the world's most pressing public health problem...

antitussive or expectorant activity. Cough can also be reported in terms ofits intensity, loudness, duration, pressure, flow and volume relationships, cough “resistances” can be calculated to reflect the inertial, elastic and flow-resistive components of respiration, and changes in breathing mechanics in the upper and lower airways may be recorded.’ Under the same sponsorship as the Charlottesv...

Kinetics of oxidation of mephenesin and guaifenesin by sodium N-chlorobenzenesulfonamide (CAB) have been investigated in HCl medium at 303 K. The oxidation behaviour is similar for both the substrates. The rate shows a first order dependence on both [CAB]0 and [HCl], and is fractional in [substrate]0. The orders individually in [H ] and [Cl] are fractional. The variation of ionic strength and a...

A simple LC/MSMS method has been developed and fully validated to determine concentrations and characterize the concentration vs. time course of methocarbamol (MCBL) and guaifenesin (GGE) in plasma after a single intravenous dose and multiple oral dose administrations of MCBL to conditioned Thoroughbred horses. The plasma concentration-time profiles for MCBL after a single intravenous dose of 1...

Accurate and sensitive methods were developed for simultaneous determination of methocarbamol and ibuprofen or diclofenac potassium in their binary mixtures, and in the presence of a methocarbamol related substance (guaifenesin) using mean centering of the ratio spectra method. The results obtained were statistically compared with the reported HPLC methods; no significant difference between the...

Guaifenesin, a highly water-soluble active (50 mg/mL), classified as a BCS class I drug. Owing to its poor flowability and compressibility, formulating tablets especially high-dose one, may be a challenge. Direct compression may not be feasible. Bilayer tablet technology applied to Mucinex®, endures challenges to deliver a robust formulation. To overcome challenges involved in bilayer-tablet ma...